Literature DB >> 25328158

Nonconventional chemical inhibitors of microRNA: therapeutic scope.

Gopal Gunanathan Jayaraj1, Smita Nahar, Souvik Maiti.   

Abstract

MicroRNAs (miRNAs) are a class of genomically encoded small RNA molecules (∼22nts in length), which regulate gene expression post transcriptionally. The term microRNA or miRNA was coined in 2001, and research in the past decade has shed light on their widespread occurrence, evolutionary conservation and tissue specific functions. It is estimated that they modulate the gene expression of approximately 60% of the mammalian genes by regulating the levels of target mRNAs to which they can bind on the basis of sequence complementarities. miRNAs are produced in a well coordinated series of steps from being transcribed in the nucleus to exerting their function in the cytoplasm. miRNAs are now implicated in diverse biological phenomena ranging from development to stress response which makes miRNAs one of the central regulatory molecules which modulate information flow along the central dogma of gene expression. More importantly, like any regulatory molecule, deregulation of miRNAs is causally associated with several diseases (mainly cancer) and is directly involved in a variety of pathophysiologies owing to their aberrant expression. Thus, modulation of miRNA levels is of prime therapeutic importance. Conventional methods of miRNA knockdown using chemically modified antisense-oligonucleotides have been explored extensively but face the challenges of modes of delivery, biostability and biodistribution. This calls for the development of more alternative and non-conventional methods to target miRNA. Small molecules targeting RNA chemical and structural space provide one such timely opportunity. In this article we first provide a brief overview of miRNA biogenesis and its disease associations. We then summarize the major developments in conventional oligonucleotide based approaches to miRNA knockdown and its status. We then focus on the more non-conventional methods like oligonucleotide enzymes and small molecules and provide an outlook on the future of such methods.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25328158     DOI: 10.1039/c4cc04514a

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN: 1359-7345            Impact factor:   6.222


  9 in total

Review 1.  Novel and emerging targeted-based cancer therapy agents and methods.

Authors:  Mohammad Hojjat-Farsangi
Journal:  Tumour Biol       Date:  2015-02-09

Review 2.  Small molecules with big roles in microRNA chemical biology and microRNA-targeted therapeutics.

Authors:  Rengen Fan; Chaocheng Xiao; Xinqiang Wan; Wenzhang Cha; Yufeng Miao; Yong Zhou; Chenglin Qin; Ting Cui; Fenglian Su; Xiangxiang Shan
Journal:  RNA Biol       Date:  2019-04-03       Impact factor: 4.652

Review 3.  HDL and microRNA therapeutics in cardiovascular disease.

Authors:  Danielle L Michell; Kasey C Vickers
Journal:  Pharmacol Ther       Date:  2016-09-03       Impact factor: 12.310

4.  Regulating miRNA-21 Biogenesis By Bifunctional Small Molecules.

Authors:  Hao Yan; Umesh Bhattarai; Zhi-Fo Guo; Fu-Sen Liang
Journal:  J Am Chem Soc       Date:  2017-03-29       Impact factor: 15.419

5.  Design, synthesis and activity of light deactivatable microRNA inhibitor.

Authors:  Hao Yan; Umesh Bhattarai; Yabin Song; Fu-Sen Liang
Journal:  Bioorg Chem       Date:  2018-07-02       Impact factor: 5.275

6.  MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.

Authors:  Tian Tian; Ma Mingyi; Xia Qiu; Yang Qiu
Journal:  Oncotarget       Date:  2016-11-29

7.  Bifunctional small molecule-oligonucleotide hybrid as microRNA inhibitor.

Authors:  Umesh Bhattarai; Wei-Che Hsieh; Hao Yan; Zhi-Fo Guo; Ashif Yasin Shaikh; Aria Soltani; Yabin Song; Danith H Ly; Fu-Sen Liang
Journal:  Bioorg Med Chem       Date:  2020-02-18       Impact factor: 3.461

Review 8.  The role of epigenetics in kidney malignancies.

Authors:  Alfredo Harb-De la Rosa; Matthew Acker; Sanjaya Swain; Murugesan Manoharan
Journal:  Cent European J Urol       Date:  2015-04-20

9.  Potent inhibition of miR-27a by neomycin-bisbenzimidazole conjugates.

Authors:  Smita Nahar; Nihar Ranjan; Arjun Ray; Dev P Arya; Souvik Maiti
Journal:  Chem Sci       Date:  2015-07-09       Impact factor: 9.825

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.